2021;6(3):e004067
Retatrutide is an investigational triple agonist peptide that targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously
Pharmacologic studies in animals have shown that suppression of food intake after peripheral administration of the GLP-1 receptor agonists exendin-4 and liraglutide is mediated by activation of GLP-1R expressed on vagal afferents as well as direct CNS GLP-1R activation, highlighting the importance of the interaction between peripheral and central receptors [31]
Engelman says ingredients to look for that include peptides, growth factors, and retinoids to support collagen
Common signs include extreme tiredness, low energy, pins and needles, muscle weakness, disturbed vision, low mood, diffuse hair loss and even premature greying